Developer docs
API playgroundTry for free, no card

Search company profiles

Bedrocan

Full company profile

uuid002owol

Namestring
Bedrocan
Legal namestring
Bedrocan International
Websiteurl
bedrocan.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Bedrocan International is a Netherlands-headquartered, privately held producer of standardised, pharmaceutical-grade medicinal cannabis founded in 1984 in Veendam. The company manufactures cannabis Active Pharmaceutical Ingredients (APIs) — dried flower (flos) and cut flos — across multiple proprietary chemovars with fixed THC:CBD ratios, including Bedrocan (22% THC), Bedrocan forte (25% THC), Bedropuur (20% THC), Bedrolina (14% CBD), Bedrobinol, Bediol, Bedrolite, and Bedica. Its core technology is a proprietary standardisation method built on stable plant genetics and vegetative propagation that prevents genetic drift, combined with automated indoor cultivation under strict environmental controls, gamma irradiation sterilisation, and the company's own GMCCP quality standard layered on top of EU-GACP. Bedrocan was the first cannabis company in the world to obtain EU-GMP certification.

The company serves four primary customer segments: (1) government health programmes, with exclusive supply to the Dutch Medicinal Cannabis Programme since 2003; (2) compounding pharmacies that prepare magistral cannabis oil preparations; (3) pharmaceutical manufacturers and drug developers sourcing cannabis APIs for product development and clinical research; and (4) healthcare professionals prescribing or dispensing cannabis-based therapy. Distribution is concentrated through exclusive channel partners — Medios AG for Germany (with planned expansion to Austria, Belgium, Italy, and Spain from 2027) and Novachem for Australia — with direct supply to pharmaceutical manufacturers globally. Production is anchored in two Netherlands facilities (combined 7,500 kg/year) and a new EU-GMP-certified Danish facility in Køge (2,300 kg/year, inaugurated 2025), with a reacquired Toronto facility entering Canadian production.

Revenue is generated through unit-priced B2B sales of cannabis APIs, wholesale flower, and — from 2026 — finished patient-facing formulations under the new Bedromed line (sublingual spray and oromucosal drops) and the Becanex PIEX 70% THC concentrate developed with Berlin-based Becanex. Pricing in the Netherlands is set by the Bureau Medicinale Cannabis at approximately €8/gram, with international pricing varying by country and distribution arrangement. The company has supplied over 15,000 kg of medicinal cannabis to German patients since exports began in 2008, reflecting a long-duration, contract-anchored revenue model with growing geographic and product-line diversification.

Short descriptiontext

Bedrocan is a Netherlands-headquartered EU-GMP-certified producer of standardised pharmaceutical-grade medicinal cannabis APIs and finished formulations, supplying government health programmes, compounding pharmacies, and pharmaceutical manufacturers across Europe, Australia, and Canada via proprietary standardisation methods and exclusive distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVeendam, Netherlands
HQ citystring
Veendam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal cannabis, pharmaceutical cannabis API, cannabis flower production, standardized cannabinoid products, cannabis active pharmaceutical ingredient
Industry4 codes
PRIMARYCRANAFAA
Adult-Use (Recreational) Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAHAG
Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAGAJ
Cannabis Accessories & Ancillary Product Delivery (Vapes, Papers, Devices)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Medicinal Cannabis API Manufacturing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cannabis API and Raw Material Sales
TypeOne Time License
Description

Bedrocan produces and sells standardised cannabis as Active Pharmaceutical Ingredients (APIs) and pharmaceutical raw materials to large and small drug developers, pharmaceutical manufacturers, and compounding pharmacies worldwide. Products are sold in various forms including flos (whole dried flower), cut flos (ground dried flower), and as inputs for extracts and formulations. The company also generates revenue from supplying the Dutch Medicinal Cannabis Programme exclusively since 2003.

bedrocan.com
2Finished Cannabinoid Formulations (Bedromed)
TypeOne Time License
Description

Bedrocan launched Bedromed, a new product line of standardised cannabinoid-based formulations including sublingual spray and oromucosal drops in various THC:CBD ratios, extending the company's API business into patient-friendly finished delivery formats.

mmjdaily.com
3Cannabis Concentrate for Compounding
TypeOne Time License
Description

Partnership with Becanex to launch Bedrocan flower as a 70% THC pharmaceutical-grade concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies, preserving the natural cannabinoid and terpene profile through proprietary extraction.

cannabisequipmentnews.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details5 tiers
1Medicinal cannabis flos/granulaat – Netherlands pharmacy
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Approximately €8 per gram for prescribed medicinal cannabis from Dutch pharmacies, as set by the Bureau Medicinale Cannabis (BMC). This is comparable to or slightly lower than coffee shop prices while offering pharmaceutical quality, consistency, and regulatory oversight.

bedrocan.com
2THC oil / cannabis oil – Dutch compounding pharmacies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices for THC-containing oil (wietolie, medicinale cannabisolie) range from €15 to €178 for a 10ml bottle, depending on THC concentration (0.5% to 10%) and whether CBD is included. Produced by compounding pharmacies using Bedrocan's cannabis APIs.

bedrocan.com
3CBD oil – Dutch pharmacy
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CBD oil from pharmacies ranges from €50 to €150 for a 10ml bottle, depending on CBD concentration. Produced from Bedrolite® raw material by pharmacies such as Transvaal Apotheek and MYCB1 Apotheek.

bedrocan.com
4Cannabis API – Australian compounding pharmacies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available in 400-gram or 3,000-gram packaging configurations for compounding pharmacies. Australian distributor Novachem handles distribution, with 10-gram packages available directly to pharmacies for patient use.

bedrocan.com
5Bedrocan® forte 25% THC – German market API
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Bedrocan® forte with 25% THC available as Active Pharmaceutical Ingredient (API) for pharmaceutical preparations in bulk packaging of 100 and 400 grams, with smaller packaging to follow. Distributed in Germany by the company's distribution partner.

bedrocan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Bedromed
Description

Standardised cannabinoid-based formulations product line including sublingual spray and oromucosal drops with various THC:CBD ratios.

mmjdaily.com
+5 more records
Core offering1 text field

Bedrocan produces and sells standardised, pharmaceutical-grade medicinal cannabis as Active Pharmaceutical Ingredients (APIs) in various chemovars with fixed THC:CBD ratios, supplied as dried flower (flos) and cut flos to pharmaceutical manufacturers, compounding pharmacies, and government medicinal cannabis programmes worldwide. The company also sells finished cannabinoid formulations (Bedromed sublingual spray and oromucosal drops) and partners to offer a 70% THC concentrate for compounding pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Consistent cannabinoid and terpene profile across every batch
+3 more records
Product overview1 text field

Bedrocan is an EU GMP-certified producer of standardised, pharmaceutical-grade medicinal cannabis. The core offering is a portfolio of cannabis Active Pharmaceutical Ingredients (APIs) — different chemovars with fixed THC:CBD ratios — sold as dried flower (flos) and as raw materials for pharmaceutical manufacturers and compounding pharmacies. The product portfolio includes: Bedrocan® (22% THC, flagship), Bedrocan® forte (25% THC), Bedropuur® (20% THC), Bedrolina® (14% CBD), Bedrobinol® (13.5% THC), Bediol® (balanced THC/CBD), Bedrolite® (high CBD), and Bedica® (indica-type). In 2026, the company launched Bedromed — a new line of standardised formulations (sublingual spray and oromucosal drops) derived from its cannabis APIs, bringing pharmaceutical-grade consistency into modern patient-friendly delivery formats. A new Becanex PIEX cannabis concentrate for compounding pharmacies is also planned for summer 2026.

Product and service11 records
1Bedrocan®
CategoryMedicinal Cannabis Flower (API)
Description

The primary standardised cannabis chemovar (Cannabis sativa L. 'Afina') with 22% THC and <1% CBD. The flagship product of Bedrocan, used as a pharmaceutical API since 2003, with consistent cannabinoid and terpene profile batch to batch.

2Bedrocan® forte (25% THC)
CategoryMedicinal Cannabis Flower (API)
Description

Enhanced version of the Bedrocan® chemovar with 25% THC (up from 22%), using the same Cannabis sativa L. 'Afina' genetics. Produced in the Danish EU-GMP facility with refined growing conditions. Complies with European Pharmacopoeia monograph.

3Bedropuur®
CategoryMedicinal Cannabis Flower (API)
Description

High-THC chemovar (Cannabis sativa L. 'Harmina') with 20% THC and <1% CBD. Originally developed as a raw material for manufacturing high-THC extracts. Available in flos and cut flos forms.

4Bedrolina®
CategoryMedicinal Cannabis Flower (API)
Description

High-CBD chemovar (Cannabis sativa L. 'Janna') with <1% THC and 14% CBD. Developed to supply CBD extracts and other CBD products. One of the most recent products in the portfolio.

5Bedrobinol®
CategoryMedicinal Cannabis Flower (API)
Description

Standardised cannabis chemovar with approximately 13.5% THC and <1% CBD. One of the original cannabis products supplied to the Dutch Medicinal Cannabis Programme since 2003.

6Bediol®
CategoryMedicinal Cannabis Flower (API)
Description

Balanced THC:CBD cannabis chemovar with approximately 6.3% THC and 8.8% CBD. One of the original products supplied to the Dutch Medicinal Cannabis Programme since 2003, also used in clinical studies such as the LUMC fibromyalgia pain study.

7Bedrolite®
CategoryMedicinal Cannabis Flower (API)
Description

High-CBD cannabis chemovar with <1% THC and approximately 8.1% CBD. Used by compounding pharmacies for CBD oil preparations. Available from Dutch pharmacies including Transvaal Apotheek and MYCB1 Apotheek.

8Bedica®
CategoryMedicinal Cannabis Flower (API)
Description

Indica-type cannabis chemovar with approximately 14.4% THC and <1% CBD. One of five cannabis strains available by prescription in the Netherlands.

9Bedromed spray
CategoryCannabinoid Formulations
Description

Standardised cannabinoid-based formulation for sublingual administration, derived from Bedrocan® and Bedrolina® cannabis APIs. Part of the new Bedromed product line offering patient-friendly delivery formats with various THC:CBD ratios. Initial availability in Germany starting August 2026.

10Bedromed drops
CategoryCannabinoid Formulations
Description

Standardised cannabinoid-based formulation for oromucosal administration, derived from Bedrocan® cannabis API. Part of the Bedromed product line. Multiple THC:CBD ratio options including THC-dominant and balanced formulations.

11Becanex PIEX Bedrocan 70% THC Concentrate
CategoryCannabis Concentrate
Description

Pharmaceutical-grade cannabis concentrate for compounding pharmacies, preserving the natural cannabinoid and terpene profile of Bedrocan flower. Jointly developed with Becanex using proprietary extraction method. Target availability summer 2026, first market Germany.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Berlin-based extraction specialist Becanex has partnered with Bedrocan to launch Bedrocan flower as a pharmaceutical-grade 70% THC concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies. The proprietary extraction method preserves the natural cannabinoid and terpene profile of the original flower. Supply is planned to begin in summer 2026, with Germany as the first market, marking the beginning of a broader product collaboration between the two firms.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-20
Description

Berlin-based Medios AG serves as Bedrocan's exclusive distribution partner for medicinal cannabis products across Germany, Spain, Belgium, Italy, and Austria. Initially covering production from Bedrocan's EU-GMP-certified Danish facility, with expansion planned from 2027. The partnership leverages Medios AG's existing pharmacy and wholesaler network, including the Cannaflos network in Germany, to streamline procurement for pharmacists who previously had to navigate a fragmented market of dozens of distributors.

3Novachem
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Australian distributor Novachem delivers Bedrocan's cannabis API products to pharmacies in 10-gram packages directly for patient use. Compounding pharmacies can order through Novachem's online portal (accessible only to registered pharmacies with an account). Novachem also handles new cannabis API products (Bedropuur® and Bedrolina®) grown at Bedrocan's Danish EU-GMP facility for the Australian market, available in 400 or 3,000 gram packaging.

bedrocan.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German medicinal cannabis producer with EU-GMP-certified cultivation, competing directly with Bedrocan in the German pharmacy channel. Both supply standardised cannabis flos to German compounding pharmacies and wholesalers and are pursuing the same German regulatory framework.

TypeBroad incumbent
Description

Canadian licensed producer with EU-GMP facilities supplying European medicinal cannabis markets. Competes in the same EU pharmacy channel as Bedrocan, with broader product portfolio and larger production scale.

TypeBroad incumbent
Description

Canadian-headquartered cannabis producer with European medicinal cannabis operations. Broad incumbent with overlapping European medicinal cannabis distribution and pharmaceutical-channel relationships.

TypeDirect peer
Description

Berlin-based medicinal cannabis distributor and producer supplying German pharmacies, with a similar channel-partner-led model to Bedrocan/Medios AG. Competes in the same German pharmacy and compounding segment with comparable product positioning.

TypeEmerging player
Description

Australian medicinal cannabis producer with EU-GMP capabilities and European expansion ambitions. Direct overlap with Bedrocan in standardised cannabis APIs and Australian market, smaller scale.

TypeBroad incumbent
Description

Canadian licensed producer with EU-GMP operations supplying the German and broader European medicinal cannabis market. Competes in the same standardised cannabis flos segment with established European distribution.

TypeEmerging player
Description

European medicinal cannabis distributor and processor supplying pharmacies in Germany, the UK, and other European markets. Comparable in channel model (specialised cannabis distribution into European pharmacies) to Bedrocan's relationship with Medios AG.

TypeDirect peer
Description

GMP-certified cannabis concentrate and API producer supplying pharmaceutical and wellness customers. Directly comparable as a pharma-grade cannabis API/extract supplier targeting similar drug-development and compounding pharmacy customers.

TypeDirect peer
Description

Developer of Sativex and Epidiolex, the most established pharmaceutical-grade cannabis-derived medicines globally. Direct peer in pharmaceutical-grade cannabis standardisation, regulatory rigour, and prescriber/clinical channel.

10Tilray Brands
TypeBroad incumbent
Description

Large Canadian cannabis producer with EU-GMP-certified operations and significant German and European medicinal cannabis distribution. Overlaps with Bedrocan in pharmaceutical-grade supply and the German pharmacy channel but operates at meaningfully larger scale and across adult-use and CPG.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bedrocan

Medicinal Cannabis API Manufacturingbedrocan.com

Bedrocan is a Netherlands-headquartered EU-GMP-certified producer of standardised pharmaceutical-grade medicinal cannabis APIs and finished formulations, supplying government health programmes, compounding pharmacies, and pharmaceutical manufacturers across Europe, Australia, and Canada via proprietary standardisation methods and exclusive distribution partners.

What Bedrocan does

Bedrocan International is a Netherlands-headquartered, privately held producer of standardised, pharmaceutical-grade medicinal cannabis founded in 1984 in Veendam. The company manufactures cannabis Active Pharmaceutical Ingredients (APIs) — dried flower (flos) and cut flos — across multiple proprietary chemovars with fixed THC:CBD ratios, including Bedrocan (22% THC), Bedrocan forte (25% THC), Bedropuur (20% THC), Bedrolina (14% CBD), Bedrobinol, Bediol, Bedrolite, and Bedica. Its core technology is a proprietary standardisation method built on stable plant genetics and vegetative propagation that prevents genetic drift, combined with automated indoor cultivation under strict environmental controls, gamma irradiation sterilisation, and the company's own GMCCP quality standard layered on top of EU-GACP. Bedrocan was the first cannabis company in the world to obtain EU-GMP certification.

The company serves four primary customer segments: (1) government health programmes, with exclusive supply to the Dutch Medicinal Cannabis Programme since 2003; (2) compounding pharmacies that prepare magistral cannabis oil preparations; (3) pharmaceutical manufacturers and drug developers sourcing cannabis APIs for product development and clinical research; and (4) healthcare professionals prescribing or dispensing cannabis-based therapy. Distribution is concentrated through exclusive channel partners — Medios AG for Germany (with planned expansion to Austria, Belgium, Italy, and Spain from 2027) and Novachem for Australia — with direct supply to pharmaceutical manufacturers globally. Production is anchored in two Netherlands facilities (combined 7,500 kg/year) and a new EU-GMP-certified Danish facility in Køge (2,300 kg/year, inaugurated 2025), with a reacquired Toronto facility entering Canadian production.

Revenue is generated through unit-priced B2B sales of cannabis APIs, wholesale flower, and — from 2026 — finished patient-facing formulations under the new Bedromed line (sublingual spray and oromucosal drops) and the Becanex PIEX 70% THC concentrate developed with Berlin-based Becanex. Pricing in the Netherlands is set by the Bureau Medicinale Cannabis at approximately €8/gram, with international pricing varying by country and distribution arrangement. The company has supplied over 15,000 kg of medicinal cannabis to German patients since exports began in 2008, reflecting a long-duration, contract-anchored revenue model with growing geographic and product-line diversification.

Bedrocan firmographics

Firmographics
Name
Bedrocan
Legal name
Bedrocan International
Website
https://bedrocan.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
51–100 employees
Short description
Bedrocan is a Netherlands-headquartered EU-GMP-certified producer of standardised pharmaceutical-grade medicinal cannabis APIs and finished formulations, supplying government health programmes, compounding pharmacies, and pharmaceutical manufacturers across Europe, Australia, and Canada via proprietary standardisation methods and exclusive distribution partners.
Ownership category
akta.pro rank

Bedrocan industry classification

Industry
Product category
Medicinal Cannabis API Manufacturing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRANAFAA
Adult-Use (Recreational) Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAHAG
Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAGAJ
Cannabis Accessories & Ancillary Product Delivery (Vapes, Papers, Devices)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medicinal cannabis
  • Pharmaceutical cannabis API
  • Cannabis flower production
  • Standardized cannabinoid products
  • Cannabis active pharmaceutical ingredient

Where Bedrocan is headquartered

Location

Headquarters

HQ city
Veendam
HQ country
Netherlands
HQ region
Europe

Offices4 records

Markets served

Bedrocan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Cannabis API and Raw Material Sales: Bedrocan produces and sells standardised cannabis as Active Pharmaceutical Ingredients (APIs) and pharmaceutical raw materials to large and small drug developers, pharmaceutical manufacturers, and compounding pharmacies worldwide. Products are sold in various forms including flos (whole dried flower), cut flos (ground dried flower), and as inputs for extracts and formulations. The company also generates revenue from supplying the Dutch Medicinal Cannabis Programme exclusively since 2003.
  2. Finished Cannabinoid Formulations (Bedromed): Bedrocan launched Bedromed, a new product line of standardised cannabinoid-based formulations including sublingual spray and oromucosal drops in various THC:CBD ratios, extending the company's API business into patient-friendly finished delivery formats.
  3. Cannabis Concentrate for Compounding: Partnership with Becanex to launch Bedrocan flower as a 70% THC pharmaceutical-grade concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies, preserving the natural cannabinoid and terpene profile through proprietary extraction.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMedicinal cannabis flos/granulaat – Netherlands pharmacy
Unit PricingPay-as-you-goTHC oil / cannabis oil – Dutch compounding pharmacies
Unit PricingPay-as-you-goCBD oil – Dutch pharmacy
Unit PricingPay-as-you-goCannabis API – Australian compounding pharmacies
Unit PricingPay-as-you-goBedrocan® forte 25% THC – German market API

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Bedrocan product offering

Product offering

Core offering

Bedrocan produces and sells standardised, pharmaceutical-grade medicinal cannabis as Active Pharmaceutical Ingredients (APIs) in various chemovars with fixed THC:CBD ratios, supplied as dried flower (flos) and cut flos to pharmaceutical manufacturers, compounding pharmacies, and government medicinal cannabis programmes worldwide. The company also sells finished cannabinoid formulations (Bedromed sublingual spray and oromucosal drops) and partners to offer a 70% THC concentrate for compounding pharmacies.

Product overview

Bedrocan is an EU GMP-certified producer of standardised, pharmaceutical-grade medicinal cannabis. The core offering is a portfolio of cannabis Active Pharmaceutical Ingredients (APIs) — different chemovars with fixed THC:CBD ratios — sold as dried flower (flos) and as raw materials for pharmaceutical manufacturers and compounding pharmacies. The product portfolio includes: Bedrocan® (22% THC, flagship), Bedrocan® forte (25% THC), Bedropuur® (20% THC), Bedrolina® (14% CBD), Bedrobinol® (13.5% THC), Bediol® (balanced THC/CBD), Bedrolite® (high CBD), and Bedica® (indica-type). In 2026, the company launched Bedromed — a new line of standardised formulations (sublingual spray and oromucosal drops) derived from its cannabis APIs, bringing pharmaceutical-grade consistency into modern patient-friendly delivery formats. A new Becanex PIEX cannabis concentrate for compounding pharmacies is also planned for summer 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Bedromed: Standardised cannabinoid-based formulations product line including sublingual spray and oromucosal drops with various THC:CBD ratios.
  • Becanex PIEX
  • Bedropuur
  • Bedrolina
  • Bedrocan
  • Bedrocan forte

Products and services

  • Bedrocan® The primary standardised cannabis chemovar (Cannabis sativa L. 'Afina') with 22% THC and <1% CBD. The flagship product of Bedrocan, used as a pharmaceutical API since 2003, with consistent cannabinoid and terpene profile batch to batch.
  • Bedrocan® forte (25% THC) Enhanced version of the Bedrocan® chemovar with 25% THC (up from 22%), using the same Cannabis sativa L. 'Afina' genetics. Produced in the Danish EU-GMP facility with refined growing conditions. Complies with European Pharmacopoeia monograph.
  • Bedropuur® High-THC chemovar (Cannabis sativa L. 'Harmina') with 20% THC and <1% CBD. Originally developed as a raw material for manufacturing high-THC extracts. Available in flos and cut flos forms.
  • Bedrolina® High-CBD chemovar (Cannabis sativa L. 'Janna') with <1% THC and 14% CBD. Developed to supply CBD extracts and other CBD products. One of the most recent products in the portfolio.
  • Bedrobinol® Standardised cannabis chemovar with approximately 13.5% THC and <1% CBD. One of the original cannabis products supplied to the Dutch Medicinal Cannabis Programme since 2003.
  • Bediol® Balanced THC:CBD cannabis chemovar with approximately 6.3% THC and 8.8% CBD. One of the original products supplied to the Dutch Medicinal Cannabis Programme since 2003, also used in clinical studies such as the LUMC fibromyalgia pain study.
  • Bedrolite® High-CBD cannabis chemovar with <1% THC and approximately 8.1% CBD. Used by compounding pharmacies for CBD oil preparations. Available from Dutch pharmacies including Transvaal Apotheek and MYCB1 Apotheek.
  • Bedica® Indica-type cannabis chemovar with approximately 14.4% THC and <1% CBD. One of five cannabis strains available by prescription in the Netherlands.
  • Bedromed spray Standardised cannabinoid-based formulation for sublingual administration, derived from Bedrocan® and Bedrolina® cannabis APIs. Part of the new Bedromed product line offering patient-friendly delivery formats with various THC:CBD ratios. Initial availability in Germany starting August 2026.
  • Bedromed drops Standardised cannabinoid-based formulation for oromucosal administration, derived from Bedrocan® cannabis API. Part of the Bedromed product line. Multiple THC:CBD ratio options including THC-dominant and balanced formulations.
  • Becanex PIEX Bedrocan 70% THC Concentrate Pharmaceutical-grade cannabis concentrate for compounding pharmacies, preserving the natural cannabinoid and terpene profile of Bedrocan flower. Jointly developed with Becanex using proprietary extraction method. Target availability summer 2026, first market Germany.

Quantifiable outcome

  • Consistent cannabinoid and terpene profile across every batch
  • +3 more outcomes

Companies that use Bedrocan

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Bedrocan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Bedrocan partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • BecanexcoreStrategic or Co-development Partner · 19 May 2026Berlin-based extraction specialist Becanex has partnered with Bedrocan to launch Bedrocan flower as a pharmaceutical-grade 70% THC concentrate (Becanex PIEX Bedrocan 70% THC Concentrate) for compounding pharmacies. The proprietary extraction method preserves the natural cannabinoid and terpene profile of the original flower. Supply is planned to begin in summer 2026, with Germany as the first market, marking the beginning of a broader product collaboration between the two firms.
  • Medios AGcoreChannel Partner/ Reseller/ Distributor · 20 January 2026Berlin-based Medios AG serves as Bedrocan's exclusive distribution partner for medicinal cannabis products across Germany, Spain, Belgium, Italy, and Austria. Initially covering production from Bedrocan's EU-GMP-certified Danish facility, with expansion planned from 2027. The partnership leverages Medios AG's existing pharmacy and wholesaler network, including the Cannaflos network in Germany, to streamline procurement for pharmacists who previously had to navigate a fragmented market of dozens of distributors.
  • NovachemcoreChannel Partner/ Reseller/ DistributorAustralian distributor Novachem delivers Bedrocan's cannabis API products to pharmacies in 10-gram packages directly for patient use. Compounding pharmacies can order through Novachem's online portal (accessible only to registered pharmacies with an account). Novachem also handles new cannabis API products (Bedropuur® and Bedrolina®) grown at Bedrocan's Danish EU-GMP facility for the Australian market, available in 400 or 3,000 gram packaging.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Bedrocan competitors and assessment

Company assessment

Direct peers

  • Demecan: German medicinal cannabis producer with EU-GMP-certified cultivation, competing directly with Bedrocan in the German pharmacy channel. Both supply standardised cannabis flos to German compounding pharmacies and wholesalers and are pursuing the same German regulatory framework.
  • Cantourage: Berlin-based medicinal cannabis distributor and producer supplying German pharmacies, with a similar channel-partner-led model to Bedrocan/Medios AG. Competes in the same German pharmacy and compounding segment with comparable product positioning.
  • MediPharm Labs: GMP-certified cannabis concentrate and API producer supplying pharmaceutical and wellness customers. Directly comparable as a pharma-grade cannabis API/extract supplier targeting similar drug-development and compounding pharmacy customers.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Sativex and Epidiolex, the most established pharmaceutical-grade cannabis-derived medicines globally. Direct peer in pharmaceutical-grade cannabis standardisation, regulatory rigour, and prescriber/clinical channel.

Broad incumbents

  • Aurora Cannabis: Canadian licensed producer with EU-GMP facilities supplying European medicinal cannabis markets. Competes in the same EU pharmacy channel as Bedrocan, with broader product portfolio and larger production scale.
  • Canopy Growth Corporation: Canadian-headquartered cannabis producer with European medicinal cannabis operations. Broad incumbent with overlapping European medicinal cannabis distribution and pharmaceutical-channel relationships.
  • OrganiGram Holdings: Canadian licensed producer with EU-GMP operations supplying the German and broader European medicinal cannabis market. Competes in the same standardised cannabis flos segment with established European distribution.
  • Tilray Brands: Large Canadian cannabis producer with EU-GMP-certified operations and significant German and European medicinal cannabis distribution. Overlaps with Bedrocan in pharmaceutical-grade supply and the German pharmacy channel but operates at meaningfully larger scale and across adult-use and CPG.

Emerging players

  • Little Green Pharma: Australian medicinal cannabis producer with EU-GMP capabilities and European expansion ambitions. Direct overlap with Bedrocan in standardised cannabis APIs and Australian market, smaller scale.
  • Therismos: European medicinal cannabis distributor and processor supplying pharmacies in Germany, the UK, and other European markets. Comparable in channel model (specialised cannabis distribution into European pharmacies) to Bedrocan's relationship with Medios AG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bedrocan social profiles

Digital presence

Bedrocan compliance and trust

Trust signal

Compliance5 records

Bedrocan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bedrocan leadership team

Management profile

Number of profiles

Profiles5 records

Bedrocan funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bedrocan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bedrocan

What does Bedrocan do?

Bedrocan produces and sells standardised, pharmaceutical-grade medicinal cannabis as Active Pharmaceutical Ingredients (APIs) in various chemovars with fixed THC:CBD ratios, supplied as dried flower (flos) and cut flos to pharmaceutical manufacturers, compounding pharmacies, and government medicinal cannabis programmes worldwide. The company also sells finished cannabinoid formulations (Bedromed sublingual spray and oromucosal drops) and partners to offer a 70% THC concentrate for compounding pharmacies.

Is Bedrocan a public or private company?

Bedrocan is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bedrocan founded?

Bedrocan was founded in 1984. It employs 51 to 100 people.

Where is Bedrocan based?

Bedrocan is headquartered in Veendam, Netherlands, in the Europe region.

How does Bedrocan make money?

Three revenue lines are on record. Cannabis API and Raw Material Sales are the primary driver. The others are finished Cannabinoid Formulations (Bedromed) and cannabis Concentrate for Compounding.

Who are Bedrocan's main competitors?

Direct peers on record are Demecan, Cantourage, MediPharm Labs and GW Pharmaceuticals (Jazz Pharmaceuticals). Broad incumbents are Aurora Cannabis, Canopy Growth Corporation, OrganiGram Holdings and Tilray Brands. Emerging players are Little Green Pharma and Therismos.

Does Bedrocan have an API?

No public API is recorded for Bedrocan.

What industry is Bedrocan in?

Bedrocan's product category is Medicinal Cannabis API Manufacturing. Its primary akta.pro industry code is CRANAFAA, Adult-Use (Recreational) Cannabis Dispensaries, with a secondary code of CRANAHAG, Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders). Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBoy at heart of cannabis oil campaign in new fight for life-saving drugBedrocan, the Dutch company making Bedrolite cannabis oil, has gone bankrupt, threatening supply for UK families like Alfie Deacon and Louis Matthews. Alfie, seizure-free for eight years, and Louis, seizure-free for six, face potential loss of treatment. The UK has about six months of stock, with no reliable UK source.BBCMedicinal cannabis supplies at risk as drug company goes bankruptBedrocan's bankruptcy threatens Bedrolite supplies for epilepsy patients, with Dutch inventory export halted. Families like Alfie Deacon's and Louis Petit's face potential treatment loss, while the UK has about six months of stock. The government is working with the Dutch to secure additional supply.MjbizdailyCannabis producer Bedrocan declared bankrupt in NetherlandsA Dutch court declared Bedrocan, the Netherlands' sole licensed medical cannabis cultivator, bankrupt on Thursday. The state will shift to international imports for domestic MMJ supply, with no alternate supplier announced. A creditor's meeting is set for Dec. 22.ForbesDutch Court Declares Medical Cannabis Pioneer Bedrocan BankruptA Dutch court declared Bedrocan bankrupt, ending its supply of medical cannabis to the Dutch government's program. The ruling affects around 7,000 patients, as the company's contract with the Office of Medicinal Cannabis ended in January. The new supply system is not yet in place, with changes expected by July 2028.EIN PresswireBedrocan and Becanex Launch Strategic Product Cooperation — Joint Market Presence in GermanyBedrocan and Becanex are launching a strategic product cooperation, with Germany as the first joint market. The kick-off is set for May 2026, and German import volumes rose from 72 tonnes in 2024 to 201 tonnes in 2025. The partnership includes joint R&D and healthcare-professional information activities.Cannabis Equipment NewsBedrocan Flower Will Soon Be Available as Concentrate for CompoundingDutch medicinal cannabis manufacturer Bedrocan has partnered with Berlin-based extraction specialist Becanex to launch Bedrocan flower as a pharmaceutical-grade concentrate for compounding pharmacies for the first time. The jointly developed product, called Becanex PIEX Bedrocan 70% THC Concentrate, preserves the natural cannabinoid and terpene profile of the original flower through Becanex's proprietary extraction method. The companies aim to begin supplying the concentrate by summer 2026, with Germany as the first market, marking the beginning of a broader product collaboration between the two firms.MMJDailyBedrocan launches cannabinoid formulationsBedrocan has announced the launch of Bedromed, a new product line of standardised cannabinoid-based formulations including sublingual spray and oromucosal drops. The new line extends the company's existing Bedrocan and Bedrolina cannabis APIs into patient-friendly delivery formats with various THC:CBD ratios. CEO Jaap Erkelens stated the launch represents a significant portfolio expansion bringing pharmaceutical-grade consistency to patients in modern delivery forms.Business of Cannabis2026 Cannabis Consolidation: Mergers, Battles & PartnershipsHigh Tide's German subsidiary Remexian Pharma secured dual court victories against competitor Vayamed, with the Berlin Court of Appeal partially granting an injunction barring Vayamed from distributing disparaging statements about Remexian's Medicines Act compliance while Hamburg Regional Court issued a separate preliminary injunction against Malta-registered Dr Ansay Ltd for violations of Germany's Medicines Advertising Act. Australian medicinal cannabis companies Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff, positioning the entity as one of the largest vertically integrated cannabis businesses globally. Berlin-based Medios AG entered the medical cannabis market by securing exclusive distribution rights for Bedrocan's products across Germany, Spain, Belgium, Italy, and Austria, initially covering production from Bedrocan's EU-GMP certified facility in Denmark with expansion planned from 2027.MMJDailyMedios AG becomes Bedrocan’s exclusive distribution partner for GermanyBedrocan has appointed Medios AG as its exclusive distribution partner for medicinal cannabis products in Germany, with plans to expand to Austria, Belgium, Italy, and Spain. Medios AG, headquartered in Berlin, will distribute cannabis produced at Bedrocan's Danish facility to pharmacies and wholesalers throughout Germany, leveraging the existing network of Cannaflos for a seamless transition. The partnership aims to streamline procurement for German pharmacists who previously had to navigate a fragmented market of dozens of distributors to source Bedrocan's products.BedrocanAustralian compounding pharmacies & API cannabisBedrocan has launched two new cannabis active pharmaceutical ingredient (API) products, Bedropuur® and Bedrolina®, specifically for Australian compounding pharmacies, alongside its existing product, Bedrocan®. These products will be cultivated in a new EU-GMP-certified facility in Denmark and are designed to allow pharmacies to customize cannabis medicines for patients' needs, with new formulations expected to be developed later this year.